window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-64619718-7');


Inhibitors of the protein kinase IRAK4 have been developed by others as potential agents in the treatment of cancer and inflammation.  A collaboration between Vernalis Research and Asahi Kasei Pharmaceuticals used fragment and structure-based discovery methods to identify novel series of IRAK4 inhibitors that have been assessed in different disease models.  The project is available for out-licensing from Asahi Kasei Pharmaceuticals.

2021-02-02T12:15:04+00:00February 2nd, 2021|